本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Theravance Biopharma Inc.

17.02
-0.0200-0.12%
盤後17.020.00000.00%19:30 EDT
成交量:68.37萬
成交額:1,164.23萬
市值:8.82億
市盈率:16.29
高:17.05
開:17.03
低:17.02
收:17.04
52周最高:21.03
52周最低:13.08
股本:5,182.83萬
流通股本:2,585.69萬
量比:1.86
換手率:2.64%
股息:- -
股息率:- -
每股收益(TTM):1.05
每股收益(LYR):2.06
淨資產收益率:20.91%
總資產收益率:1.33%
市淨率:3.04
市盈率(LYR):8.26

資料載入中...

2025/01/21

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/11/14

超過5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/11/14

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/11/12

重要事件披露

Form 8-K - Current report
2024/09/23

重要事件披露

Form 8-K - Current report
2024/09/10

重要事件披露

Form 8-K - Current report
2024/09/09

超過5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/08/16

超過5%披露

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
2024/08/09

超過5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/08/08

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/08/05

重要事件披露

Form 8-K - Current report
2024/06/11

超過5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/05/15

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/05/13

重要事件披露

Form 8-K - Current report
2024/05/09

重要事件披露

Form 8-K - Current report
2024/05/03

超過5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/03/05

超過5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/03/01

年度報告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/02/28

重要事件披露

Form 8-K - Current report
2024/02/26

重要事件披露

Form 8-K - Current report